Mohsin Shah

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4047737/publications.pdf

Version: 2024-02-01

		1040056	839539
18	1,217	9	18
papers	citations	h-index	g-index
18	18	18	1988
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS ONE, 2016, 11, e0160221.	2.5	373
2	Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease. Annals of Internal Medicine, 2018, 168, 121.	3.9	341
3	Perceived Stress, Sources and Severity of Stress among medical undergraduates in a Pakistani Medical School. BMC Medical Education, 2010, 10, 2.	2.4	242
4	Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Seminars in Arthritis and Rheumatism, 2019, 48, 736-740.	3.4	90
5	Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease. Annals of Internal Medicine, 2018, 169, 133.	3.9	44
6	Self-reported tobacco smoking practices among medical students and their perceptions towards training about tobacco smoking in medical curricula: A cross-sectional, questionnaire survey in Malaysia, India, Pakistan, Nepal, and Bangladesh. Substance Abuse Treatment, Prevention, and Policy, 2010, 5, 29.	2.2	42
7	Diagnosis and management of immuneâ€related adverse effects of immune checkpoint therapy in the emergency department. Journal of the American College of Emergency Physicians Open, 2020, 1, 1637-1659.	0.7	17
8	Effect of anti–tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis—A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic. Journal of the American Academy of Dermatology, 2021, 84, 161-163.	1.2	13
9	Intuitive weights of harm for therapeutic decision making in smear-negative pulmonary Tuberculosis: an interview study of physicians in India, Pakistan and Bangladesh. BMC Medical Informatics and Decision Making, 2014, 14, 67.	3.0	9
10	SARS-CoV-2 and Anti-Cardiolipin Antibodies. Clinical Medicine Insights: Case Reports, 2020, 13, 117954762098038.	0.7	8
11	Safety of Immune Checkpoint Blockade in Patients with Cancer and Preexisting Autoimmune Diseases and/or Chronic Inflammatory Disorders. Journal of Immunotherapy and Precision Oncology, 2019, 2, 59-64.	1.4	8
12	The physician's unique role in preventing violence: a neglected opportunity?. BMC Medicine, 2012, 10, 146.	5 . 5	6
13	Extramedullary Plasmacytoma Involving the Trachea: A Case Report and Literature Review. Journal of Emergency Medicine, 2019, 57, e65-e67.	0.7	6
14	Very high <scp>PDâ€L1</scp> expression as a prognostic indicator of overall survival among patients with advanced <scp>nonâ€small</scp> cell lung cancer receiving antiâ€ <scp>PD</scp> â€(L)1 monotherapies in routine practice. Pharmacoepidemiology and Drug Safety, 2022, 31, 1121-1126.	1.9	6
15	Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. Blood Cells, Molecules, and Diseases, 2012, 48, 199-201.	1.4	5
16	Serious immuneâ€related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review. Head and Neck, 2019, 41, 4036-4050.	2.0	3
17	Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians ShouldÂKnow. Annals of Emergency Medicine, 2020, 75, 264-286.	0.6	3
18	Association of cancer screening and residing in a coal-polluted East Asian region with overall survival of lung cancer patients: a retrospective cohort study. Scientific Reports, 2020, 10, 17432.	3.3	1